Your browser doesn't support javascript.
Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine.
Arunachalam, Prabhu S; Feng, Yupeng; Ashraf, Usama; Hu, Mengyun; Walls, Alexandra C; Edara, Venkata Viswanadh; Zarnitsyna, Veronika I; Aye, Pyone Pyone; Golden, Nadia; Miranda, Marcos C; Green, Kristyn W M; Threeton, Breanna M; Maness, Nicholas J; Beddingfield, Brandon J; Bohm, Rudolf P; Scheuermann, Sarah E; Goff, Kelly; Dufour, Jason; Russell-Lodrigue, Kasi; Kepl, Elizabeth; Fiala, Brooke; Wrenn, Samuel; Ravichandran, Rashmi; Ellis, Daniel; Carter, Lauren; Rogers, Kenneth; Shirreff, Lisa M; Ferrell, Douglas E; Deb Adhikary, Nihar R; Fontenot, Jane; Hammond, Holly L; Frieman, Matthew; Grifoni, Alba; Sette, Alessandro; O'Hagan, Derek T; Van Der Most, Robbert; Rappuoli, Rino; Villinger, Francois; Kleanthous, Harry; Rappaport, Jay; Suthar, Mehul S; Veesler, David; Wang, Taia T; King, Neil P; Pulendran, Bali.
  • Arunachalam PS; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA.
  • Feng Y; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA.
  • Ashraf U; Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
  • Hu M; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA.
  • Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Edara VV; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
  • Zarnitsyna VI; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, and Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Aye PP; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30329, USA.
  • Golden N; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Miranda MC; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Green KWM; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Threeton BM; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Maness NJ; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Beddingfield BJ; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Bohm RP; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Scheuermann SE; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Goff K; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Dufour J; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Russell-Lodrigue K; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Kepl E; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Fiala B; Tulane National Primate Research Center, Covington, LA 70433, USA.
  • Wrenn S; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Ravichandran R; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Ellis D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Carter L; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Rogers K; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Shirreff LM; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Ferrell DE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Deb Adhikary NR; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Fontenot J; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Hammond HL; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Frieman M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Grifoni A; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Sette A; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
  • O'Hagan DT; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
  • Van Der Most R; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
  • Rappuoli R; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
  • Villinger F; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
  • Kleanthous H; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Rappaport J; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Suthar MS; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
  • Veesler D; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
  • Wang TT; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • King NP; GSK, Rockville, MD 20850, USA.
  • Pulendran B; GSK, Rixensart 1330, Belgium.
Sci Transl Med ; 14(658): eabq4130, 2022 08 17.
Article in English | MEDLINE | ID: covidwho-1992934
ABSTRACT
Despite the remarkable efficacy of COVID-19 vaccines, waning immunity and the emergence of SARS-CoV-2 variants such as Omicron represents a global health challenge. Here, we present data from a study in nonhuman primates demonstrating durable protection against the Omicron BA.1 variant induced by a subunit SARS-CoV-2 vaccine comprising the receptor binding domain of the ancestral strain (RBD-Wu) on the I53-50 nanoparticle adjuvanted with AS03, which was recently authorized for use in individuals 18 years or older. Vaccination induced neutralizing antibody (nAb) titers that were maintained at high concentrations for at least 1 year after two doses, with a pseudovirus nAb geometric mean titer (GMT) of 1978 and a live virus nAb GMT of 1331 against the ancestral strain but not against the Omicron BA.1 variant. However, a booster dose at 6 to 12 months with RBD-Wu or RBD-ß (RBD from the Beta variant) displayed on I53-50 elicited high neutralizing titers against the ancestral and Omicron variants. In addition, we observed persistent neutralization titers against a panel of sarbecoviruses, including SARS-CoV. Furthermore, there were substantial and persistent memory T and B cell responses reactive to Beta and Omicron variants. Vaccination resulted in protection against Omicron infection in the lung and suppression of viral burden in the nares at 6 weeks after the final booster immunization. Even at 6 months after vaccination, we observed protection in the lung and rapid control of virus in the nares. These results highlight the durable and cross-protective immunity elicited by the AS03-adjuvanted RBD-I53-50 nanoparticle vaccine.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Sci Transl Med Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Scitranslmed.abq4130

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Sci Transl Med Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Scitranslmed.abq4130